Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive  ( Ph+ )  Acute Lymphoblastic Leukemia  ( ALL )  - Ascentage Pharma Group  ( NASDAQ:AAPG )